Felis ISSN 2398-2950

Clorazepate

Contributor(s): Simon Platt

Introduction

Name

  • Clorazepate dipotassium.

Class of drug

  • Benzodiazepine pro-drug.

Description

Chemical name

  • Clorazepate dipotassium.

Molecular formula

  • C16H11ClK2N2O4.

Molecular weight

  • 408.9.

Physical properties

  • Light yellow fine powder.
  • Very soluble in water.
  • Slightly soluble in alcohol.

Storage requirements

  • Capsules and tablets should be stored in tight, light resistant containers at room temperature.
  • Unstable in the presence of water or alcohol.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Adjunctive short-term anticonvulsant.
  • Treatment of anxiety or phobia related disorders.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • CNS depressants - additive effects may occur.
  • Phenobarbital - serum levels may increase when clorazepate and phenobarbital are used in conjunction.
  • Phenytoin - increased serum levels of phenytoin and decreased levels of clorazepate may result from their combination.
  • Rifampin - can induce hepatic microsomal enzymes and decrease the pharmacological effect of clorazepate.
  • Cimetidine and erythromycin may decrease the metabolism of clorazepate.

with diagnostic tests

  • Clorazepate may decrease the thyroidal uptake of I123 or I131.
  • Clorazepate may increase serum alkaline phosphatase, alanine transaminase and serum cholesterol levels.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed.
  • Forrester S D, Wilcke J R, Jacobson J D & Dyer K R (1993) Effects of 44-day administration of Phenobarbital on disposition of clorazepate in dogs.Am J Vet Res54, 1136-1138PubMed.
  • Brown S A & Forrester S D (1991)Serum disposition of oral clorazepate from regular-release and sustained-delivery tablets in dogs.J Vet Pharmacol Therap14, 426-429 PubMed.
  • Forrester S D, Brown S A, Lees G E & Hartsfield S M (1990)Disposition of clorazepate in dogs after single- and multiple-dose oral administration.Am J Vet Res51, 2001-2005 PubMed.
  • Scherkl R, Kurudi D & Frey H H (1989)Clorazepate in dogs: tolerance to the anticonvulsant effect and signs of physical dependence.Epilepsy Res3, 144-150 PubMed.

ADDED